In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously "undruggable" cancer-driving ...

In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a ...

Small molecule drugs are low-molecular-weight, organic compounds used to treat a wide range of conditions. Here's what you should know.

Colon cancer is often driven by cancer stem cells, which resist treatment and lead to relapse. In a recent study, researchers ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a ...

Classical psychedelics like LSD, psilocybin, and mescaline are known for activating the 5-HT2A serotonin receptor, but a new ...

Scientists have studied a new target for antibiotics in the greatest detail yet—in the fight against antibiotic resistance. The "molecular machine" flagellum is essential for bacteria to cause ...

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the ...

Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular ...